Navigation Links
Lilly Confirms Date and Conference Call For Fourth-Quarter and Full-Year 2009 Financial Results Announcement
Date:1/16/2010

INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the fourth quarter and full year of 2009 on Thursday, January 28, 2010. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

The conference call will be held from 9:00 a.m. to 10:00 a.m. EST. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at www.lilly.com. The webcast of the conference call will be available for replay through February 26, 2010.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY

(Logo: http://www.newscom.com/cgi-bin/
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 ... CHDX ) today announced the completion of its ... $24.00 per share in cash.  Healthy Harmony is an ... ("Fosun") and Ms. Roberta Lipson , the CEO ... agreement was adopted by Chindex,s stockholders at a special ...
(Date:9/30/2014)... ANGELES , Sept. 30, 2014 ... biopharmaceutical research and development company specializing in oncology, ... 2b clinical trial evaluating aldoxorubicin compared to topotecan ... (SCLC) who have relapsed or were refractory to ... the widely-used chemotherapeutic agent, doxorubicin. CytRx has received ...
(Date:9/29/2014)... N.Y. and PARIS , ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... an investigational therapy that blocks IL-4 and IL-13 signaling, ... moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did ... data suggest the potential of dupilumab for use in ...
Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7
... U.S. Dept. of Defense Continues Study of Copper ... Infections and Improving Indoor Air Quality, NEW ... clinical trails determining the,antimicrobial effectiveness of copper, brass ... Association, announced CDA President Andrew G.,Kireta Sr. ...
... Serious Adverse Reactions, BERKELEY HEIGHTS, N.J., Nov. ... findings from the initial clinical,dosing of G4544, the ... treatment for diseases associated with accelerated bone loss. ... volunteers, has shown good,tolerance with oral bioavailability of ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... If you were to create a list ... it say? Would you place a high value on charisma? ... create a leadership “wish list,” the truth is that just ... there different types of leaders. But if good leaders come ... programs that account for this kind of diversity? , ...
(Date:9/30/2014)... Lexington, KY (PRWEB) September 30, 2014 ... million people in the United States alone have sleep ... treated; and of those treated, many cannot tolerate their ... pressure supplied through a nasal mask) – which supports ... good night’s sleep has become especially valuable, and increasingly ...
(Date:9/30/2014)... is proud to announce the release of The ... by Frank Guglielmo and Sudhanshu Palsule ... their leadership coaching experience to introduce Social Leadership – a ... that leaders must adopt in order to thrive in today’s ... review of The Social Leader in Dialogue Reviews. , Author ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 ... clash,” opened Bryan W. Brickner, “and it’s about ... Political Cannabinoid Science , new on the Bryan ... research from the National Institutes of Health (PubMed). ... regarding: de-homeostatic sleep disturbances, REM transitions, aging with ...
Breaking Medicine News(10 mins):Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Personality Plays a Key Role in Leadership Development 2Health News:Personality Plays a Key Role in Leadership Development 3Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2
... to have their blood sugar, blood pressure, and cholesterol ... a high-quality Medicare plan, researchers reported Tuesday. ... Medical Association, show that racial disparities are common throughout ... Amal N. Trivedi of Brown University in Providence, Rhode ...
... about personalized medicine enabled through genetic testing, slated to ... would not only involve forecasting the presence of a ... but will also enable early prevention strategies. ... cardiovascular diseases, but will unravel the genetic blue prints ...
... of folic acid every day could have better chance of getting ... form of vitamin B is used in our bodies to make ... body before she is pregnant, it can help prevent major birth ... study involving more than 18,000 women for the first time revealed ...
... Regular exercise combined with nicotine replacement therapy could help ... colleagues at the Otto Wagner Hospital// in Vienna enrolled ... nicotine-replacement therapy, reported the online edition of health magazine ... be quitters enrolled in an exercise programme., ,The ...
... to a recent study, women with a twin are at upto ... without one//. ,The study was conducted on over 800 ... premature ovarian failure (POF) at the age of 40 was 3-5 ... causes the ovaries to shut down ten years or earlier than ...
... and toddlers, reports a major study conducted on the side effects ... government proposed immunization for all kids of the age 6 months ... a sharp rise in the number of children getting vaccinated. This ... 2 years as often as the old people. ,This ...
Cached Medicine News:Health News:Medicare Marked by Widespread Racial disparities 2Health News:Folic Acid Supplements Could Help Conception 2
... system includes: Mx3005P instrument and custom ... five (5) filters. The standard filter ... HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 ... notebook computer, Mx3005P analysis software, Beacon ...
... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
Medicine Products: